ILC2の記憶と喘息再発を制御するエピジェネティックな仕組みを解明(Researchers Reveal Epigenetic Mechanisms Regulating ILC2 Memory and Asthma Recurrence)

ad

2025-10-13 中国科学院(CAS)

中国科学院上海栄養・健康研究所の研究チームは、慢性喘息の再発を引き起こす免疫記憶細胞「ILC2」の記憶形成を支配するエピジェネティック機構を解明した。ILC2はアレルゲン刺激で活性化し、再曝露時に強い炎症を誘導するが、その分子基盤は不明だった。研究では、クロマチンリモデラーBrg1(Smarca4)がILC2のクロマチン構造を開き、代謝関連遺伝子Hif1aやLdhaの発現を促進して解糖系を活性化することを発見。これによりILC2が長期的に「代謝的記憶」を保持し、再刺激時に急速増殖することが判明した。マウスでBrg1またはHif1aを欠損させると炎症が軽減し、Brg1阻害剤Compound 14はステロイドより強力に再発炎症を抑制した。Brg1を標的とすることで、喘息やアレルギー疾患の根本的治療に道を開く可能性が示された。研究成果は『Journal of Allergy and Clinical Immunology』誌に掲載。

ILC2の記憶と喘息再発を制御するエピジェネティックな仕組みを解明(Researchers Reveal Epigenetic Mechanisms Regulating ILC2 Memory and Asthma Recurrence)
Brg1-imprinted chromatin status controls the effector and memory group 2 innate lymphoid cell metabolism to exacerbate allergic lung inflammation. (Image provided by Dr. QIU Ju’s group)

<関連情報>

Brg1インプリントクロマチン状態はエフェクターおよびメモリーグループ2自然リンパ球細胞の代謝を制御し、アレルギー性肺炎症を悪化させる Brg1-imprinted chromatin status controls effector and memory group 2 innate lymphoid cell metabolism to exacerbate allergic lung inflammation

Jupei Tang, PhD ∙ Hanxiao Sun, MD ∙ Huidan Chang, MS ∙ … ∙ Jinxin Qiu, PhD∙ Jun Qin, PhD ∙ Ju Qiu, PhD
The Journal of Allergy and Clinical Immunology  Published:September 17, 2025
DOI:https://doi.org/10.1016/j.jaci.2025.08.029

Abstract

Background

The chromatin status fluctuates with effector and memory group 2 innate lymphoid cell (ILC2) responses. How this intricate coordination affects allergic lung inflammation remains unclear.

Objective

We examined how the chromatin remodeler brahma-related gene 1 (Brg1) regulates ILC2s in allergic lung inflammation.

Methods

Acute lung allergic inflammation was induced with papain in wild-type, Il5Cre/+Smarca4flox/flox (Smarca4f/f), Il5Cre/+Hif1af/f, and Il5Cre/+Ldhaf/f mice. Secondary lung inflammation was induced with low-dose IL-33 in papain-primed Il5Cre/+Smarca4f/f mice. ATAC-Seq, RNA sequencing, and Brg1 CUT&Tag analyses were performed on naive ILC2s, effector ILC2s (ILC2eff), memory ILC2s (ILC2mem), IL-33–challenged Brg1-deficient ILC2s, Brg1-deficient ILC2mem, and human ILC2s treated with or without the Brg1 inhibitor Compound 14. ILC2 metabolism was analyzed by 13C glucose isotype tracing and metabolic flux, Seahorse, and SCENITH assays. Compound 14 was used to treat mouse and humanized mouse models of allergic lung inflammation.

Results

Brg1 expression was upregulated in asthma patients’ ILC2s and was induced by IL-33. Brg1 promoted IL-5+ and IL-13+ ILC2 expansion and exacerbated both acute and secondary lung inflammation. Brg1 imprinted the chromatin landscape favoring aerobic glycolysis, the metabolic process reinforced in ILC2eff and ILC2mem. Brg1-augmented Hif1a enhancer accessibility was a sustained epigenetic signature in ILC2mem inherited from ILC2eff, and Hif1α enhanced ILC2eff and ILC2mem responses. Pharmacologic inhibition of Brg1, rather than dexamethasone treatment, in acute phase alleviated secondary lung inflammation.

Conclusion

Brg1 promotes the expansion of pathogenic ILC2eff and ILC2mem and exacerbates allergic lung inflammation. Mechanistically, Brg1 increases the chromatin accessibility and transcription of Hif1a and Ldha, key factors reinforcing ILC2 glycolysis metabolism.

生物化学工学
ad
ad
Follow
ad
タイトルとURLをコピーしました